Jiangsu Hengrui Medicine FY2025 publishes ESG report; MSCI ESG rating climbs to AA

Reuters03-26
<a href="https://laohu8.com/S/600276">Jiangsu Hengrui</a> Medicine FY2025 publishes ESG report; MSCI ESG rating climbs to AA
  • Hengrui released its fifth ESG report, covering environmental protection, social responsibilities, and corporate governance across the company and subsidiaries included in its financial statements.
  • Environmental disclosures include ISO 14001 certification for 7 core manufacturing entities, representing 70% coverage.
  • Energy conservation measures reported carbon emissions reductions of more than 7,434.75 tons and photovoltaic projects generated 1.14 million kWh.
  • Healthcare access disclosures state 20 products/indications were added to the updated national reimbursement drug list and equitable pricing strategies were implemented for at least 10 products in markets including Vietnam and Pakistan.
  • Governance disclosures include 3 shareholders’ meetings and 10 board meetings, and anti-corruption training coverage of 100% of employees with 238,070 training hours.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12067927), on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment